Varuma logo

Varuma

Europe, Basel-Stadt, Switzerland, Basel

Description

Varuma is a venture capital firm that invests in the healthcare sector.

Investor Profile

Varuma has made 3 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series B (33%)
  • Series Unknown (33%)
  • Series C (33%)

Country Focus

  • Switzerland (100%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Varuma frequently co-invest with?

Gimv
Europe, Antwerpen, Belgium, Antwerpen
Co-Investments: 1
Novartis Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 2
CA
Europe, Hovedstaden, Denmark, Copenhagen
Co-Investments: 1
3i Group
Europe, England, United Kingdom, London
Co-Investments: 1
Aravis Ventures
Europe, Zurich, Switzerland, Zürich
Co-Investments: 1
NGN Capital
North America, New York, United States, New York
Co-Investments: 1
BB
Europe, Solothurn, Switzerland, Wiler
Co-Investments: 1
Dow
North America, Michigan, United States, Midland
Co-Investments: 1
HI
Europe, Baden-Wurttemberg, Germany, Heidelberg
Co-Investments: 1
Oxford Bioscience Partners
North America, Massachusetts, United States, Boston
Co-Investments: 1

What are some of recent deals done by Varuma?

NovImmune

Plan-les-ouates, Geneve, Switzerland

NovImmmune develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders.

BiotechnologyMedicalPharmaceutical
Series UnknownMay 12, 2009
Amount Raised: $54,800,000
Addex Therapeutics

Plan-les-ouates, Geneve, Switzerland

Addex Therapeutics is a biopharmaceutical company that discovers and develops allosteric modulators for human health.

BiotechnologyHealth CareMedicalPharmaceutical
Series CSep 19, 2006
Amount Raised: $31,688,931
Santhera Pharmaceuticals

Liestal, Basel-Landschaft, Switzerland

Santhera Pharmaceuticals develops and markets pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases.

BiotechnologyHealth CarePharmaceutical
Series BDec 20, 2005
Amount Raised: $18,997,524